|
|
|
| Effects of Salmon Calcitonin Injection and Zoledronic Acid Injection on Bone Turnover Markers and Bone Mineral Density in Patients with Postmenopausal Osteoporosis |
| YUE Jianbiao, GOU Jing, WEI Xuandi, et al |
| Sichuan Orthopaedic Hospital, Sichuan Chengdu 610041, China |
|
|
|
|
Abstract Objective: To study the effects of salmon calcitonin and zoledronic acid on bone turnover markers (BTMs) and bone mineral density (BMD) in patients with postmenopausal osteoporosis (PMOP). Methods: 74 patients with PMOP in our hospital from April 2017 to April 2018 were selected and evenly divided into two groups according to the simple randomization method (each n=37). The two groups were given an intravenous infusion of 5 mg of zoledronic acid on the basis of basic treatments of calcium carbonate D3, calcitriol and lifestyle intervention (once a year), and observation group was additionally given an intravenous infusion of 50 IU/d of salmon calcitonin (changed to once for every other day after 2 weeks, twice for 1 week after 1 month, administration time of 3 months per year). The clinical effects were compared between the two groups at 1 year after treatment. Results: The effective rates of treatment in observation group and control group were 94.29% and 77.14% respectively (P<0.05), and there was a statistically significant difference in the clinical efficacy between the two groups (P<0.05). After treatment, the VAS scores of bone pain in the two groups were significantly decreased (P<0.05), and the VAS score in observation group was lower than that in control group. The levels of serum PINP and β-CTX were significantly decreased in the two groups (P<0.05) while the level of serum 25OHD was significantly increased in the two groups, and the levels of PINP and β-CTX in observation group were significantly lower than those in control group. The BMD values of lumbar vertebrae L1~4, femoral neck and Ward’’s triangle were significantly increased in the two groups (P<0.05), and the BMD of each part in observation group was higher than that in control group (P<0.05). There were no significant differences in the incidence rates of adverse reactions such as headache and dizziness, nausea and vomiting, fever, myalgia, arthralgia and influenza-like symptoms during treatment between the two groups (P>0.05), and the incidence rates of fractures during treatment were 8.57% and 17.14% respectively in the two groups (P>0.05). Conclusion: Zoledronic acid combined with salmon calcitonin in the treatment of PMOP can alleviate bone pain, reduce the expression of BTMs and promote BMD. The clinical effect of zoledronic acid alone has obvious advantages over zoledronic acid alone.
|
|
|
|
|
|
[1] 刘奋斗,丁海.绝经后骨质疏松症对股骨近端的生物学影响[J].中国骨质疏松杂志,2017,23(5):672~675.
[2] Nishizawa Y,Ohta H,Miura M,et al.Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis(2012 edition)[J].Bone Miner Metab,2013,31(1):1~15.
[3] Kanis JA,Mccloskey EV,Johansson H,et al.European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J].Osteoporosis Int,2013,24(1):399~428.
[4] 杨志新,杨磊,钱阳晶.唑来膦酸对骨质疏松患者骨痛、骨密度和血清骨代谢标志物的影响[J].解放军医药杂志,2017,29(4):85~88.
[5] 汤勇,陈雄,刘佳,等.鲑鱼降钙素对骨质疏松症患者骨痛影响的随机对照临床研究文献meta分析[J].临床药物治疗杂志,2016,14(5):32~36.
[6] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,20(5):413~443.
[7] Zhu H,Jiang J,Wang Q,et al.Associations between ERα/βgene polymorphisms and osteoporosis susceptibility and bone mineral density in postmenopausal women:a systematic review and meta-analysis[J].BMC Endocr Disord,2018,18(1):11~16.
[8] Al-Agha AE,Hayatalhazmi RS.Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia[J].Saudi Med,2015,36(11):1312~1318.
[9] 邹艺,李笑,王倩,等.鲑鱼降钙素注射液与唑来膦酸钠注射液治疗绝经后骨质疏松症的临床疗效对比[J].中国骨质疏松杂志,2018,24(08):1044~1048. |
|
|
|
2019, Vol. 25 
